GlassScriptPhysician profile
Joseph Baratta
NPI 1871681163
$541.72
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $124 · 2022: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $157.91 | 2019-2020 | |
| Philips North America LLC | $79.62 | 2020 | |
| Davol INC. | $59.09 | 2019-2022 | |
| Inari Medical, INC. | $58.46 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $53.43 | 2022 | |
| Merck Sharp & Dohme LLC | $41.31 | 2019 | |
| Smith+Nephew, INC. | $20.00 | 2019 | |
| Abbott Laboratories | $17.10 | 2019 | |
| Tactile Systems Technology INC | $15.62 | 2020 | |
| Ethicon US, LLC | $13.89 | 2019 | |
| Angiodynamics, INC. | $13.84 | 2019 | |
| Medtronic Vascular, INC. | $11.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Baratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.